The article reports that venture capital (VC) firms have started to demand post-marketing control plans from companies seeking funding. VC firms are increasingly using the Risk Evaluation and Mitigation Strategy (REMS) planning requirement introduced by the Food and Drug Administration Amendments Act (FDAAA) of 2007. REMS is expected by investors to help expedite approval and extend the market exclusivity of a product.